Evidence map›Paper›PMID 38750076›Full record

ArticleNature communications2024

Identifying proteomic risk factors for cancer using prospective and exome analyses of 1463 circulating proteins and risk of 19 cancers in the UK Biobank.

Keren Papier, Joshua R Atkins, Tammy Y N Tong, Kezia Gaitskell, Trishna Desai, Chibuzor F Ogamba, Mahboubeh Parsaeian, Gillian K Reeves, Ian G Mills, Tim J Key and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Exploring potential biomarkers of diffuse large B-cell lymphoma through multi-dimensional data.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  10. Article
  11. Review
  12. Plasma proteomic signatures improve risk stratification and personalized screening for gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Observational
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Keren Papier *Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. keren.papier@ndph.ox.ac.uk.ORCID http://orcid.org/0000-0002-4102-6835
Joshua R Atkins *Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-0821-1112
Tammy Y N TongCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-0284-8959
Kezia GaitskellCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-2474-1159
Trishna DesaiCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Chibuzor F OgambaCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-3778-311X
Mahboubeh ParsaeianCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Gillian K ReevesCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Ian G MillsNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-5347-5083
Tim J KeyCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-2294-307X
Karl Smith-Byrne *Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-1932-7463
Ruth C Travis *Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Funding

Cancer Research UK 29017Cancer Research UK 29186Cancer Research UK (CRUK) C8221/A29017Cancer Research UK (CRUK) C8221/A29186Wellcome Trust
6 · The paper itself

Abstract

The availability of protein measurements and whole exome sequence data in the UK Biobank enables investigation of potential observational and genetic protein-cancer risk associations. We investigated associations of 1463 plasma proteins with incidence of 19 cancers and 9 cancer subsites in UK Biobank participants (average 12 years follow-up). Emerging protein-cancer associations were further explored using two genetic approaches, cis-pQTL and exome-wide protein genetic scores (exGS). We identify 618 protein-cancer associations, of which 107 persist for cases diagnosed more than seven years after blood draw, 29 of 618 were associated in genetic analyses, and four had support from long time-to-diagnosis ( > 7 years) and both cis-pQTL and exGS analyses: CD74 and TNFRSF1B with NHL, ADAM8 with leukemia, and SFTPA2 with lung cancer. We present multiple blood protein-cancer risk associations, including many detectable more than seven years before cancer diagnosis and that had concordant evidence from genetic analyses, suggesting a possible role in cancer development.

Indexed as

Biological Specimen BanksExomeNeoplasmsProteomicsAgedBlood ProteinsExome SequencingFemaleGenetic Predisposition to DiseaseHumansIncidenceMaleMiddle AgedProspective StudiesRisk FactorsUK BiobankBlood Proteins

Identifiers

PMID38750076
PMCPMC11096312

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.